Published in Cancer Prev Res (Phila) on November 01, 2009
Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal (2012) 1.96
Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63
Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics (2010) 1.33
Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem (2010) 1.30
Tea and cancer prevention: epidemiological studies. Pharmacol Res (2011) 1.27
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer (2012) 1.22
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) (2011) 1.13
Notes from the field: "green" chemoprevention as frugal medicine. Cancer Prev Res (Phila) (2012) 1.11
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem (2010) 1.08
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
Cancer prevention by green tea: evidence from epidemiologic studies. Am J Clin Nutr (2013) 1.01
Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) (2010) 1.00
Chemopreventive potential of natural compounds in head and neck cancer. Nutr Cancer (2010) 0.95
Pharmacokinetic and chemoprevention studies on tea in humans. Pharmacol Res (2011) 0.93
Going Green: The Role of the Green Tea Component EGCG in Chemoprevention. J Carcinog Mutagen (2013) 0.93
Chemopreventive potential of flavonoids in oral squamous cell carcinoma in human studies. Nutrients (2013) 0.92
Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells. J Cancer Res Clin Oncol (2012) 0.92
Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics (2012) 0.91
Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG-The Role of EGFR Signaling and "Lipid Raft". J Oncol (2011) 0.86
Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells. PLoS One (2014) 0.86
Natural products for cancer prevention. Semin Oncol Nurs (2012) 0.86
Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials. J Carcinog (2011) 0.85
Phytomedicine in otorhinolaryngology and pulmonology: clinical trials with herbal remedies. Pharmaceuticals (Basel) (2012) 0.84
Tea consumption and the risk of five major cancers: a dose-response meta-analysis of prospective studies. BMC Cancer (2014) 0.84
Epigenetic mechanisms in oral carcinogenesis. Future Oncol (2012) 0.83
Protection of dietary polyphenols against oral cancer. Nutrients (2013) 0.82
Challenging the effectiveness of green tea in primary and tertiary cancer prevention. J Cancer Res Clin Oncol (2012) 0.82
Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response. PLoS One (2012) 0.82
Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS One (2013) 0.81
Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol (2013) 0.81
Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev Res (Phila) (2014) 0.81
The chemopreventive properties and therapeutic modulation of green tea polyphenols in oral squamous cell carcinoma. ISRN Oncol (2011) 0.81
Oral premalignancy: the roles of early detection and chemoprevention. Otolaryngol Clin North Am (2013) 0.79
Role of retinoic acid in the modulation of benzo(a)pyrene-DNA adducts in human hepatoma cells: implications for cancer prevention. Toxicol Appl Pharmacol (2010) 0.78
Oral cancer prevention advances with a translational trial of green tea. Cancer Prev Res (Phila) (2009) 0.78
Tea consumption and risk of head and neck cancer. PLoS One (2014) 0.78
Chemoprevention of oral cancer: Green tea experience. J Nat Sci Biol Med (2014) 0.77
Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth. Oncotarget (2016) 0.77
High-throughput, quantitative analysis of acrolein-derived DNA adducts in human oral cells by immunohistochemistry. J Histochem Cytochem (2012) 0.76
A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study. BMC Complement Altern Med (2012) 0.76
Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents. Mol Nutr Food Res (2016) 0.76
Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials. Eur J Clin Nutr (2016) 0.76
Chemopreventive and Anticancer Activities of Allium victorialis var. platyphyllum Extracts. J Cancer Prev (2014) 0.75
ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases. J Oncol (2017) 0.75
Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate. Asian Pac J Trop Biomed (2014) 0.75
Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers (Basel) (2017) 0.75
Integrative Medicine in Head and Neck Cancer. Otolaryngol Head Neck Surg (2016) 0.75
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics (1975) 18.25
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res (2003) 5.04
Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer (1984) 4.46
Why drinking green tea could prevent cancer. Nature (1997) 3.78
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Tea and cancer. J Natl Cancer Inst (1993) 3.31
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res (2000) 2.71
Angiogenesis inhibited by drinking tea. Nature (1999) 2.31
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res (2003) 2.21
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
Perspectives for cancer prevention with natural compounds. J Clin Oncol (2009) 1.99
Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol (2003) 1.94
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol (2005) 1.93
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol Biomarkers Prev (1995) 1.70
Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998. Cancer (2007) 1.63
Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol (2006) 1.61
Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr (2004) 1.46
Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J (2005) 1.45
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) (2008) 1.44
Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev Res (Phila) (2009) 1.41
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol (2002) 1.36
Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol (2001) 1.33
Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res (1993) 1.33
Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene (1998) 1.29
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene (1997) 1.22
Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med (1997) 1.21
Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res (2002) 1.20
Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun (2000) 1.19
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst (1997) 1.19
Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett (2002) 1.17
p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev (2008) 1.13
Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem (2006) 1.09
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer (2008) 1.06
A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 1.06
Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res (2001) 1.05
Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem (2002) 1.02
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst (2003) 1.00
Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila) (2009) 0.98
Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med (1999) 0.97
Anticarcinogenic effects of (-)-epigallocatechin gallate. Prev Med (1992) 0.95
Increased genetic damage in oral leukoplakia from high risk sites: potential impact on staging and clinical management. Cancer (2001) 0.95
Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A/J mice. Neoplasia (2007) 0.90
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila) (2009) 0.90
Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E). Cancer Prev Res (Phila) (2009) 0.89
Catechin metabolism: glutathione conjugate formation catalyzed by tyrosinase, peroxidase, and cytochrome p450. Chem Res Toxicol (2001) 0.88
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) (2009) 0.87
Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res (1997) 0.85
Early genetic changes during upper aerodigestive tract tumorigenesis. J Cell Biochem Suppl (1993) 0.83
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
Human epicardial adipose tissue is a source of inflammatory mediators. Circulation (2003) 6.31
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature (2010) 3.37
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Subcellular-resolution molecular imaging within living tissue by fiber microendoscopy. Opt Express (2007) 3.01
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol (2009) 2.75
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem (2002) 2.62
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
Malignant pleural mesothelioma. J Clin Oncol (2009) 2.16
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2012) 2.14
Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res (2006) 2.13
Focus on head and neck cancer. Cancer Cell (2004) 2.11
Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics (2008) 2.09
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
Multispectral optical imaging device for in vivo detection of oral neoplasia. J Biomed Opt (2008) 2.03
Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med (2012) 1.98
Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc Natl Acad Sci U S A (2008) 1.98
Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol (2002) 1.94
Understanding the biological basis of autofluorescence imaging for oral cancer detection: high-resolution fluorescence microscopy in viable tissue. Clin Cancer Res (2008) 1.92
A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res (2002) 1.87
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
In vivo fiber-optic confocal reflectance microscope with an injection-molded plastic miniature objective lens. Appl Opt (2005) 1.83
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol (2003) 1.78
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol (2006) 1.72
Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol (2011) 1.72
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70